Dalteparin: Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
Saline: Saline in prophylactic doses administered daily if screening criteria are satisfied.
Study summary
This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria
The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:
i) Patients with severe TBI defined as GCS of ≤8, or
ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:
1. Requiring invasive mechanical ventilation at the time of screening
2. Increased ICB on repeat CT scan compared to initial CT scan
iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury
iv) ≥ 18 years of age
Exclusion Criteria
All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:
i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products
ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive
iii) Known septic endocarditis
iv) Uncontrollable active bleeding
v) Known major blood clotting disorders
vi) Known acute gastroduodenal ulcer (with active bleeding)
vii) Severe uncontrolled hypertension (i.e. BP\>210 despite medications)
viii) Known diabetic or hemorrhagic retinopathy
ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period
x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)
xi) Known presence of irreversible coagulopathies
xii) Known Pregnancy
xiii) Participants extremely low weight (\<45 kg), or extremely high weight (\>120kg)
xiv) Not expected to survive more than 48 hours from admission
Primary outcome measure(s)
Clinically important VTE — 8 days Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of:
1. Symptomatic, objectively-confirmed pulmonary embolism (PE), or
2. Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or
3. Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1
Trial sites (12)
Facility
City
Region
Status
Foothills Medical Centre
Calgary
Alberta
Recruiting
Royal Alexandra Hospital
Edmonton
Alberta
Recruiting
University of Alberta Hospital
Edmonton
Alberta
Recruiting
Vancouver General Hospital
Vancouver
British Columbia
Recruiting
Queen Elizabeth II Health Sciences Centre
Halifax
Nova Scotia
Recruiting
Hamilton Health Sciences Centre
Hamilton
Ontario
Recruiting
Kingston General Hospital
Kingston
Ontario
Recruiting
The Ottawa Hospital
Ottawa
Ontario
Recruiting
Sunnybrook Health Science Centre
Toronto
Ontario
Recruiting
Unity Health Toronto
Toronto
Ontario
Recruiting
Hopital de L'Enfant-Jesus
Québec
Quebec
Recruiting
Royal University Hospital
Saskatoon
Saskatchewan
Recruiting
More Sunnybrook Health Sciences Centre trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.